摘要
目的 分析血清凝血酶敏感蛋白-1(TSP-1)、甲胎蛋白(AFP)水平与晚期食管癌患者新辅助放化疗预后的关系。方法 前瞻性选取本院2018年1月—2021年6月收治的150例晚期食管癌患者作为研究对象,收集基线资料,检测治疗前血清TSP-1、AFP水平,实施新辅助放化疗,评估患者预后,将患者划分为预后不良组和预后良好组,比较2组基线资料、血清TSP-1、AFP水平,采用回归分析检验血清TSP-1、AFP水平与晚期食管癌患者新辅助放化疗预后的关系,并检测治疗前血清TSP-1、AFP水平对晚期食管癌患者新辅助放化疗预后的预测效能。结果 150例晚期食管癌患者中,有60例预后不良,有90例预后良好;初步比较2组基线资料后,经回归分析检验结果显示,晚期食管癌患者血清TSP-1水平表达下调、血清AFP水平表达上调是预后不良的危险因素(OR>1,P<0.05);绘制ROC发现,晚期食管癌治疗前血清TSP-1、AFP水平单项及联合预测预后不良的AUC均>0.80,均有一定预测价值。结论 晚期食管癌患者行新辅助放化疗治疗后,预后风险仍较高,血清TSP-1表达下调、AFP水平表达上调是预后不良的风险因子,两者可用于预测患者预后不良发生风险。
Objective This paper aims to analyze the relationship between the levels of serum thrombospondin-1(TSP-1) and alpha fetoprotein(AFP) and the prognosis of patients with advanced esophageal cancer after neoadjuvant chemoradiotherapy. Methods A total of 150 patients with advanced esophageal cancer treated in our hospital from January 2018 to June 2021 were prospectively selected as the research subjects. The baseline data were collected, serum TSP-1 and AFP levels were detected before treatment, neoadjuvant chemoradiotherapy was used, the prognosis of patients was evaluated, and the patients were divided into poor prognosis group and good prognosis group. The baseline data and serum TSP-1 and AFP levels were compared between the two groups, regression analysis test was used to examine the relationship between serum TSP-1 and AFP levels and the prognosis of patients with advanced esophageal cancer after neoadjuvant chemoradiotherapy, and the serum levels of TSP-1 and AFP before treatment were detected to predict the prognosis of patients with advanced esophageal cancer after neoadjuvant chemoradiotherapy. Results Among 150 cases of patients with advanced esophageal cancer, 60 cases had poor prognosis and 90 cases had good prognosis;after preliminary comparison of baseline data between the two groups, through regression analysis test, the results showed that the down-regulation of serum TSP-1 level and up-regulation of serum AFP level were risk factors for poor prognosis in patients with advanced esophageal cancer(OR>1, P<0.05). ROC was drawn and showed that the AUC of serum TSP-1 and AFP levels before treatment alone and in combination in predicting poor prognosis of patients with advanced esophageal cancer was greater than 0.80, which had certain predictive value. Conclusion In patients with advanced esophageal cancer after neoadjuvant chemoradiotherapy, the risk of prognosis is still high. Down-regulation of serum TSP-1 and up-regulation of AFP are risk factors for poor prognosis, and both can be used to predict the risk of poor prognosis of patients.
作者
张萌
张向东
夏永欣
饶石磊
木亚林
ZHANG Meng;ZHANG Xiang-dong;XIA Yong-xin;RAO Shi-lei;MU Ya-lin(Department of Gastroenterology,Nanyang Central Hospital,Henan 473000,China;不详)
出处
《中国卫生检验杂志》
CAS
2022年第24期3003-3006,3010,共5页
Chinese Journal of Health Laboratory Technology
基金
河南省医学科技攻关计划项目(2018020220)。
关键词
食管癌
晚期
凝血酶敏感蛋白-1
甲胎蛋白
新辅助
放化疗
预后
Esophageal cancer
Advanced stage
Thrombospondin-1
Alpha fetoprotein
Neoadjuvant
Chemoradiotherapy
Prognosis
